[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621961":3},{"organization":4,"outcomesModule":7,"designInfo":45,"detailedDescription":11,"studyPopulation":11,"armGroups":51,"interventions":62,"overallOfficials":11,"centralContacts":70,"locations":76,"responsibleParty":92,"collaborators":11,"id":96,"slug":97,"hasResults":98,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":11,"eligibilityCriteria":102,"healthyVolunteers":98,"sex":103,"minAge":104,"maxAge":11,"enrollmentInfo":105,"targetDuration":11,"studyType":108,"phases":109,"briefSummary":111,"conditions":112,"keywords":11,"overallStatus":79,"whyStopped":11,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":124},{"fullName":5,"class":6},"Beijing Anzhen Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Transradial Access Success Rate Within 10 Minutes",null,"Intra-procedure",[14,17,19,21,23,25,28,30,33,35,37,39,41,43],{"measure":15,"description":11,"timeFrame":16},"Success Rate of Transradial Access Carotid Artery Stenting","Immediately post-procedure",{"measure":18,"description":11,"timeFrame":12},"Primary Success Rate of Transradial Access Establishment",{"measure":20,"description":11,"timeFrame":12},"Transradial-to-Transfemoral Conversion Rate",{"measure":22,"description":11,"timeFrame":12},"X-ray Radiation Exposure",{"measure":24,"description":11,"timeFrame":16},"Clinician User Experience Assessment",{"measure":26,"description":11,"timeFrame":27},"National Institutes of Health Stroke Scale (NIHSS) Score","Pre-discharge",{"measure":29,"description":11,"timeFrame":27},"Post-Procedure Modified Rankin Scale (mRS) Score",{"measure":31,"description":11,"timeFrame":32},"Incidence Rate of Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)","Pre-discharge，30 days post-procedure",{"measure":34,"description":11,"timeFrame":32},"Incidence Rate of All-Cause Death",{"measure":36,"description":11,"timeFrame":32},"Incidence Rate of Any Stroke",{"measure":38,"description":11,"timeFrame":32},"Incidence Rate of Target Vessel-Related Ischemic Stroke",{"measure":40,"description":11,"timeFrame":32},"Incidence Rate of Any Myocardial Infarction",{"measure":42,"description":11,"timeFrame":32},"Incidence Rate of Any Revascularization",{"measure":44,"description":11,"timeFrame":27},"Incidence Rate of Radial Artery Occlusion",{"allocation":46,"interventionModel":47,"interventionModelDescription":11,"primaryPurpose":48,"observationalModel":11,"timePerspective":11,"maskingInfo":49},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":50,"maskingDescription":11,"whoMasked":11},"NONE",[52,57],{"label":53,"type":54,"description":11,"interventionNames":55},"Composite-Tip Transradial Neurovascular Distal Access Catheter","EXPERIMENTAL",[56],"Device: Composite-Tip Transradial Neurovascular Distal Access Catheter",{"label":58,"type":59,"description":11,"interventionNames":60},"Straight or Single-Curve Tip Guiding Catheter","ACTIVE_COMPARATOR",[61],"Device: Straight or Single-Curve Tip Guiding Catheter",[63,67],{"type":64,"name":53,"description":65,"armGroupLabels":66,"otherNames":11},"DEVICE","Carotid Artery Stenting via Transradial Access Using a Composite-Tip Neurovascular Distal Access Catheter",[53],{"type":64,"name":58,"description":68,"armGroupLabels":69,"otherNames":11},"Carotid Artery Stenting via Transradial Access Using Straight or Single-Curve Tip Guiding Catheter",[58],[71],{"name":72,"role":73,"phone":74,"phoneExt":11,"email":75},"Xu Guo","CONTACT","+86-13810124068","guo_ball@hotmail.com",[77],{"facility":78,"status":79,"city":80,"state":11,"zip":81,"country":82,"countryCode":83,"cosmosGeoPoint":84,"geoPoint":89,"contacts":90},"Beijing Anzhen Hospital. Capital Medical University","RECRUITING","Beijing","100029","China","CN",{"type":85,"coordinates":86},"Point",[87,88],116.39723,39.9075,{"lat":88,"lon":87},[91],{"name":72,"role":73,"phone":74,"phoneExt":11,"email":75},{"type":93,"investigatorFullName":94,"investigatorTitle":95,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Guo Xu","Associate Chief Physician","100621961","safety-and-efficacy-of-a-novel-composite-tip-guiding-catheter-in-transcarotid-artery-stenting-via-transradial-access-100621961",false,"NCT07377422","Safety and Efficacy of a Novel Composite-Tip Guiding Catheter in Transcarotid Artery Stenting Via Transradial Access","Safety and Efficacy of a Novel Composite-Tip Guiding Catheter in Transcarotid Artery Stenting Via Transradial Access: A Prospective, Multicenter, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Patients who are candidates for endovascular intervention with CTA-confirmed stenosis in the common carotid artery or C1 segment of internal carotid artery(Symptomatic: ≥50% stenosis; Asymptomatic: 70%-99% stenosis）（NASCET criteria) ;\n\n   * Symptomatic carotid artery stenosis: Non-disabling ischemic stroke or transient ischemic symptoms (TIA, including hemispheric events or transient monocular blindness) within 180 days prior to randomization;\n\n     * Asymptomatic Carotid Stenosis: No history or examination findings suggestive of ipsilateral carotid ischemic symptoms(Non-carotid symptoms, contralateral carotid symptoms, symptom onset \\>180 days prior to randomization, or vertebrobasilar symptoms are classified as asymptomatic).\n3. Palpable radial pulse and negative Allen's test (confirming adequate ulnar collateral circulation);\n4. Feasible transradial access with achievable device delivery to the target lesion per operator assessment;\n5. Patients or legally authorized representatives comprehend the study purpose, voluntarily participate with signed informed consent, and commit to complete follow-up.\n\nExclusion Criteria:\n\n1. Patients with severe vascular tortuosity\u002Fdissection, extensive or diffuse atherosclerotic lesions involving the aortic arch or proximal common carotid artery, or post-surgical anatomy impeding catheter delivery;\n2. Severe stenosis, aneurysms ≥5mm in maximum diameter, arteriovenous malformations (AVM), or other significant cerebrovascular diseases in ipsilateral intracranial\u002Fextracranial arteries beyond the target vessel;\n3. Patients requiring simultaneous bilateral carotid interventions;\n4. Contraindicated in patients with severe allergies to interventional devices or agents related to carotid stenting (e.g., lidocaine, contrast agents, aspirin, clopidogrel);\n5. Preprocedural mRS ≥3;\n6. Progressive stroke within 2 weeks, hemorrhagic transformation of ischemic stroke within 3 months, or spontaneous intracranial hemorrhage within 12 months;\n7. Severe hematologic disorders (active bleeding, severe anemia, coagulopathy, or transfusion dependency), severe heart failure, severe hepatic\u002Frenal impairment, or acute coronary syndrome;\n8. Malignancy or life expectancy \\\u003C1 year.","ALL","18 Years",{"count":106,"type":107},204,"ESTIMATED","INTERVENTIONAL",[110],"NA","This study aims to evaluate the safety and efficacy of the novel composite-tip guiding catheter for transradial access in Carotid Artery Stenting procedures",[113,114],"Transradial Carotid Artery Stenting","Novel Composite-tip Guiding Catheter","2026-09-30",{"date":117,"type":118},"2026-10-05","ACTUAL",{"date":120,"type":118},"2026-05-01",{"date":122,"type":107},"2027-08-16",{"name":5,"class":6},1]